[1]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300-303.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
　Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):300-303.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
点击复制

89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
38
期数:
2014年第5期
页码:
300-303
栏目:
出版日期:
2014-09-25

文章信息/Info

Title:
Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis
作者:
刘超;  邓智勇;  刘鹏杰;  贾莉
云南省肿瘤医院核医学科, 昆明, 650118
Author(s):
Liu Chao;  Deng Zhi-yong;  Liu Peng-jie;  Jia Li
Department of Nuclear Medicine, Yunnan Provincial Tumor Hospital, Kunming 650118, China
关键词:
乳腺肿瘤; 肿瘤转移; 骨肿瘤; 二氯化锶; 唑来膦酸
Keywords:
Breast neoplasms; Neoplasms metastasis; Osteoms; 89SrCL2; Zoledronic acid
DOI:
10.3760/cma.j.issn.1673-4114.2014.05.006
摘要:
目的 探讨放射性核素二氯化锶(89SrCL2)联合唑来膦酸治疗激素依赖型乳腺癌转移性骨肿瘤的临床疗效。方法 回顾性分析64例激素依赖型乳腺癌转移性骨肿瘤患者的临床资料,将所有患者分为3组:89SrCL2治疗组22例;唑来膦酸治疗组21例;89SrCL2联合唑来膦酸治疗组21例;观察治疗后转移病灶疗效、骨痛缓解情况、生活质量状况、骨髓抑制反应情况。结果 89SrCL2治疗骨转移病灶有效率为36.4%(8/22),视觉模拟评分下降率为77.3%(17/22),全身状况KPS评分提高率为63.6%(14/22),27.2%(6/22)的患者出现骨髓抑制反应;唑来膦酸治疗后骨转移病灶有效率为33.3%(7/21),视觉模拟评分下降率为71.4%(15/21),全身状况KPS评分提高率为52.4%(11/21),19.0%(4/21)的患者出现骨髓抑制反应;89SrCL2联合唑来膦酸治疗骨转移病灶有效率为42.9%(9/21),视觉评分下降率为90.5%(19/21),全身状况KPS评分提高率为90.5%(19/21),33.3%(7/21)的患者出现骨髓抑制反应。结论 89SrCL2联合唑来膦酸对激素依赖型乳腺癌转移性骨肿瘤的疗效明显,不良反应小,联合治疗效果优于89SrCl2和唑来膦酸单独治疗。
Abstract:
Objective To discuss the clinical effects of radionuclide 89SrCL2 combined zoledronic acid treatment for hormone dependent breast neoplasm metastatic osteoma. Methods Clinical data of 64 patients with hormone dependent breast neoplasm metastatic osteoma were analyzed retrospectively. All of these patients were divided into 3 groups:one group of 22 cases treated with 89SrCL2 (89SrCL2 group);another group of 21 cases treated with zoledronic acid (zoledronic acid group);and the last group of 21 cases treat-ed with 89SrCL2 and zoledronic acid (combination group). Then patients’ metastatic lesion curative effects, the condition of bone pain remission, quality of life and bone marrow inhibitory reaction after treatment were observed. Results The effective rate, visual analogue scale decline rate, whole body KPS score in-crease rate and bone marrow inhibitory reaction rate of the 89SrCL2 group were 36.4% (8/22), 77.3% (17/22), 63.6% (14/22), 27.2% (6/22), and which were 33.3% (7/21), 71.4% (15/21), 52.4% (11/21), 19.0% (4/21)and 42.9% (9/21), 90.5% (19/21), 90.5% (19/21), 33.3% (7/21)in zoledronic acid group and combination group respectively. Conclusion 89SrCL2 combined with zoledronic acid on treating hormone dependent breast neoplasm metastatic osteoma has significant curative effect, and can relieve pain with less adverse reactions, and the combined treatment effects are better than that of 89SrCL2 or zoledronic acid alone.

参考文献/References:

[1] Kozlow W,Guise TA.Breast cancer metastasis to bone:mechanisms of osteolysis and implications for therapy[J].J Mammary Gland Biol Neoplasia,2005,10(2):169-180.
[2] Mundy GR.Metastasis to bone:causes,consequences and therapeutic opportunities[J].Nat Rev Cancer,2002,2(8):584-593.
[3] 吕靖,马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述,2007,13(1):62-63.
[4] 刘鹏熙,周瑞芳,许锐,等.唑来膦酸与帕米膦酸二钠治疗乳腺癌骨转移性疼痛的近期疗效观察[J/OL].中华乳腺病杂志:电子版,2008,(4):402-406[2014-01-13].http://cjbd.xnyy.cn/cn/index.asp.
[5] Finlay IG,Mason MD,Shelley M.Radioisotopes for the palliation of metastatic bone cancer:a systematic review[J].Lancet Oncol,2005,6(6):392-400.
[6] 潘中允.放射性核素治疗学[M].北京:人民卫生出版社,2006:217.
[7] 翟士军,万卫星,吴娜静,等.89SrCL2联合唑来膦酸治疗转移性骨肿瘤的疗效观察[J].中国辐射卫生,2013,22(4):404-406.
[8] Body JJ.Clinical research update; zoledronate[J].Cancer,1997,80(8 Suppl):S1699-1701.
[9] Skerjance A,Berenson J,Hsu C,et al.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
[10] Neville-Webbe HI,Coleman RE.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med,2003,17(6):539-553.
[11] Matsumoto S,Kimuta S,Seqawa H,et al.Efficacy of the third-generation bisphosphonate,zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines[J].Lung Cancer,2005,47(1):31-39.
[12] Croucher P,Jagdev S,Coleman R.The anti-tumor potential of zoledronic acid[J].Breast,2003,12 Suppl 2:S30-36.

相似文献/References:

[1]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
　Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[2]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
　Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[3]储小飞,赵舒怡,樊赛军.肿瘤干细胞与辐射抗性的研究进展[J].国际放射医学核医学杂志,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
　chu xiaofei,zhao shuyi,fan saijun..advance progress of cancer stem cells and radioresistance[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):431.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 019]
[4]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
　Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[5]陈伟君,孙达.99Tcm-MIBI显像在乳腺癌新辅助化疗中的应用价值[J].国际放射医学核医学杂志,2015,39(6):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
　Chen Weijun,Sun Da.Clinical value of 99Tcm-MIBI imaging in neoadjuvant chemotherapy of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):487.[doi:10.3760/cma.j.issn.1673-4114.2015.06.011]
[6]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
　Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[7]张胤,陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志,2015,39(1):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
　Zhang Yin,Chen Yue.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
[8]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
　Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
[9]刘雪辉,李洪均,于鸿煦.SPECT/CT融合显像对可疑骨转移灶的诊断效能[J].国际放射医学核医学杂志,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
　Liu Xuehui,Li Hongjun,Yu Hongxu.Diagnostic efficacy of SPECT/CT fusion imaging in assessing possible bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
[10]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
　Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[11]王宇峰,刘海娜,张居洋,等.SPECT/CT融合显像对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2014,38(6):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
　Wang Yu-feng,Liu Hai-na,Zhang Ju-yang,et al.Clinical value of SPECT/CT fusion imaging in diagnosing metastatic bone lesions in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
[12]樊孝廉,鲁胜男,古炎发,等.乳腺癌患者骨病灶SPECT/CT融合显像的临床价值[J].国际放射医学核医学杂志,2013,37(4):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
　FAN Xiao-lian,LU Sheng-nan,GU Yan-fa,et al.The clinical value of SPECT/CT fusion imaging in the diagnosis of bone metastasis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):221.[doi:10.3760/cma.j.issn.1673-4114.2013.04.008]
[13]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
　YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[14]路宝士,高玉芳.血清CA15-3、CEA检测联合全身骨显像在乳腺癌骨转移中的诊断价值[J].国际放射医学核医学杂志,2011,35(2):107.[doi:10.3760/cma.j.issn.1673-4114.2011.02.010]
　LU Bao-shi,GAO Yu-fang.The value of combined examination of serum CA15-3, CEA level and whole body bone scan in the diagnosis of bone metastasis in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):107.[doi:10.3760/cma.j.issn.1673-4114.2011.02.010]
[15]佟丽娟,王明泽,王丽梅.肺癌、乳腺癌、食道癌远端骨转移特点的对比研究[J].国际放射医学核医学杂志,2011,35(1):38.[doi:10.3760/cma.j.issn.1673-4114.2011.01.011]
　TONG Li-juan,WANG Ming-ze,WANG Li-mei.Comparative study between characteristics of the lung cancer, breast cancer and esophageal cancer distal bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):38.[doi:10.3760/cma.j.issn.1673-4114.2011.01.011]
[16]袁超,陶健,袁媛,等.血清CA15-3、CEA及全身骨显像联合检查对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2009,33(6):353.[doi:10.3760/cma.j.issn.1673-4114.2009.06.011]
　YUAN Chao,TAO Jian,YUAN Yuan,et al.The diagnostic significance of CA15-3, CEA combined with whole body bone scan for bone metastases in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(5):353.[doi:10.3760/cma.j.issn.1673-4114.2009.06.011]
[17]张亶,章斌,邓胜明,等.18F-FDG PET/CT在乳腺癌术后随访中的价值[J].国际放射医学核医学杂志,2017,41(3):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]
　Zhang Dan,Zhang Bin,Deng Shengming,et al.Clinical value of 18F-FDG PET/CT in follow-up of postoperative breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]
[18]张雪辉,杨贵生,肖国有.乳腺癌骨转移的影像学诊断进展[J].国际放射医学核医学杂志,2017,41(4):278.[doi:10.3760/cma.j.issn.1673-4114.2017.04.008]
　Zhang Xuehui,Yang Guisheng,Xiao Guoyou.Imaging for diagnosis of bone metastases in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):278.[doi:10.3760/cma.j.issn.1673-4114.2017.04.008]

备注/Memo

备注/Memo:
收稿日期:2014-02-13。
通讯作者:邓智勇(Email:13888158986@163.com)
更新日期/Last Update: 1900-01-01